How Machine Learning and Artificial Intelligence can speed up the world of data processing
In this
exclusive interview conducted ahead of this year’s forum for Data Analytics for Pharma Development,
Paul Agapow, Health Informatics Director at AstraZeneca shares his views on the
world of data, with a particular
emphasise on how artificial intelligence
(AI) can help analyse and interpret huge quantities of data at all stages
of drug discovery and development. Paul also discusses the challenges of using Real
World Data (RWD) and Real World Evidence (RWE) when data is not always easily
accessible or specific.
Download our latest interview to get the answers to the following questions:
- How is RWD
becoming increasingly attractive for research?
- What are the current challenges
when using RWD/RWE?
- How do you foresee
evolutions in different segments and types of RWD for different therapeutic
areas?
- How and in what areas are ML and AI currently impacting drug discovery and development? What challenges need to be overcome to encourage wider adoption?
- How do you see Machine Learning and AI developing over the next 5 years and the impact it will have on drug discovery and development?
Please note: That all fields marked with an asterisk (*) are required.